Ani Pharmaceuticals reported $63.38M in Cash and Equivalent for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Aerie Pharmaceuticals AERI:US $ 39.44M 17M
Ani Pharmaceuticals ANIP:US $ 63.38M 13.53M
Aurora Cannabis Inc ACB:CN 429.89M 97.49M
Canopy Growth Corp WEED:CN C$ 769.5M 464.17M
Depomed DEPO:US $ 61.39M 24.58M
Eli Lilly And LLY:US $ 2622.9M 163.7M
Endo International Ordinary Shares ENDP:US $ 1413.15M 94.05M
Heron Therapeutics HRTX:US $ 56.91M 33.63M
Hikma Pharmaceutical HIK:LN 23M 1000K
Knight Therapeutics Inc GUD:CN C$ 4.61M 4.42M
Lannett LCI:US $ 106.11M 7.47M
Nektar Therapeutics NKTR:US $ 77.54M 9.55M
Novartis NVS:US $ 3625M 10227M
Omeros OMER:US $ 8.96M 91.84M
Perrigo Ordinary Shares PRGO:US $ 1965.5M 100.6M
Teva Pharmaceutical TEVA:IT 2.06B 117M
Teva Pharmaceutical Industries TEVA:US $ 2058M 117M